Vistagen Therapeutics appointed Douglas J. Williamson, M.D., as a director effective July 29, 2026. Dr. Williamson received stock options to purchase up to 40,826 shares at an exercise price of $0.2433 per share under the Company’s Director Compensation Plan. The options vest in equal annual installments over three years and have a ten-year term. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing intranasal neuroscience product candidates.

On June 30, 2026, Vistagen Therapeutics announced that its PALISADE-4 Phase 3 trial of intranasal fasedienol for acute social anxiety disorder failed to meet its primary endpoint. The least squares mean change from baseline on the Subjective Units of Distress Scale (SUDS) was -9.5 for fasedienol versus -11.4 for placebo (p=0.427), and no treatment difference was found for secondary endpoints. However, a post-hoc analysis of a subpopulation with very severe social anxiety (LSAS score ≥ 95) showed nominal statistical significance (p=0.036). The company plans to pivot its regulatory strategy toward a potential registrational pathway focused on the overall treatment of social anxiety disorder and believes cash resources will support operations into 2027. Vistagen is a biopharmaceutical company developing pherine product candidates for CNS disorders.

Margaret FitzPatrick and Joanne Curley notified the company of their decisions not to stand for re-election at the 2026 Annual Meeting of Stockholders. Vistagen Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for anxiety and stress-related disorders.

Vistagen Therapeutics, Inc. issued a press release on June 15, 2026, announcing its financial results for the fiscal year ended March 31, 2026. The company is a biotechnology firm focused on developing therapies for emotional disorders.

Vistagen Therapeutics announced on June 9, 2026, that its clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has reached the minimum patient exposures recommended under the ICH E1 international regulatory safety database standard. The company operates in the biotechnology industry and develops pharmaceutical products.